PAR-4 as a possible new target for pancreatic cancer therapy

Expert Opinion on Therapeutic Targets

Volumn 14, Issue 6, 2010, Pages 611-620

  Azmi, Asfar S ^a   Philip, Philip A ^a   Zafar, Syed F ^a   Sarkar, Fazlul H ^a   Mohammad, Ramzi M ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Pancreatic cancer; Par 4

Indexed keywords

3,3' DIINDOLYLMETHANE; ANTINEOPLASTIC AGENT; APOG2; CISPLATIN; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; K RAS PROTEIN; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN KINASE B; PROTEINASE ACTIVATED RECEPTOR 4; SMALL MOLECULE INHIBITOR; TW 37; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GENE THERAPY; CELL SURVIVAL; CLINICAL TRIAL; DOWN REGULATION; DRUG EFFICACY; GENE EXPRESSION; GENE FUNCTION; GENE LOCATION; GENE MAPPING; GENE MUTATION; GENE TARGETING; GROWTH INHIBITION; HUMAN; NONHUMAN; PANCREAS CANCER; POINT MUTATION; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; REVIEW; TREATMENT RESPONSE; TUMOR GROWTH; VIRAL GENE THERAPY;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; DRUG DELIVERY SYSTEMS; HUMANS; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RAS PROTEINS;

EID: 77952250687     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.2010.487066     Document Type: Review

References (94)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49
2. Buchholz M, Gress TM. Molecular changes in pancreatic cancer. Expert Rev Anticancer Ther 2009;9:1487-97
3. DeNicola GM, Tuveson DA. RAS in cellular transformation and senescence. Eur J Cancer 2009; 45 (Suppl 1) : 211-6
4. Perez-Mancera PA, Tuveson DA. Physiological analysis of oncogenic K-ras. Methods Enzymol 2006;407:676-90
5. Hingorani SR, Tuveson DA. In search of an early warning system for pancreatic cancer. Cancer Biol Ther 2003;2:84-6
6. Furukawa T, Horii A. Mechanistic insights for pancreatic carcinogenesis. Nippon Rinsho 2006; 64 (Suppl 1) : 27-31
7. Sato Y, Nio Y, Song MM, et al. p53 protein expression as prognostic factor in human pancreatic cancer. Anticancer Res 1997;17:2779-88
8. Bartsch DK, Sina-Frey M, Lang S, et al. CDKN2A germline mutations in familial pancreatic cancer. Ann Surg 2002;236:730-7
9. Moskaluk CA, Hruban RH, Kern SE. p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Res 1997;57:2140-3
10. Popovic HM, Korolija M, Jakic RJ, et al. K-ras and Dpc4 mutations in chronic pancreatitis: case series. Croat Med J 2007;48:218-24
11. Perren A, Saremaslani P, Schmid S, et al. DPC4/Smad4: no mutations, rare allelic imbalances, and retained protein expression in pancreatic endocrine tumors. Diagn Mol Pathol 2003;12:181-6
12. Gerdes B, Wild A, Wittenberg J, et al. Tumor-suppressing pathways in cystic pancreatic tumors. Pancreas 2003;26:42-8
13. Olsen CC, Schefter TE, Chen H, et al. Results of a Phase I trial of 12 patients with locally advanced pancreatic carcinoma combining gefitinib, paclitaxel, and 3-dimensional conformal radiation: report of toxicity and evaluation of circulating K-ras as a potential biomarker of response to therapy. Am J Clin Oncol 2009;32:115-21
14. Jonson T, Albrechtsson E, Axelson J, et al. Altered expression of TGFB receptors and mitogenic effects of TGFB in pancreatic carcinomas. Int J Oncol 2001;19:71-81
15. Jonson T, Gorunova L, Dawiskiba S, et al. Molecular analyses of the 15q and 18q SMAD genes in pancreatic cancer. Genes Chromosomes Cancer 1999;24:62-71
16. Truty MJ, Urrutia R. Basics of TGF-beta and pancreatic cancer. Pancreatology 2007;7:423-35
17. Truty MJ, Urrutia R. Transforming growth factor-beta: what every pancreatic surgeon should know. Surgery 2007;141:1-6
18. Ahmed MM, Sheldon D, Fruitwala MA, et al. Downregulation of PAR-4, a pro-apoptotic gene, in pancreatic tumors harboring K-ras mutation. Int J Cancer 2008;122:63-70
19. Sells SF, Han SS, Muthukkumar S, et al. Expression and function of the leucine zipper protein Par-4 in apoptosis. Mol Cell Biol 1997;17:3823-32
20. Johnstone RW, See RH, Sells SF, et al. A novel repressor, par-4, modulates transcription and growth suppression functions of the Wilms' tumor suppressor WT1. Mol Cell Biol 1996;16:6945-56
21. Rangnekar VM. Apoptosis mediated by a novel leucine zipper protein Par-4. Apoptosis 1998;3:61-6
22. Lee JW, Hsiao WT, Lee KF, et al. Widespread expression of prostate apoptosis response-4 in nasopharyngeal carcinoma. Head Neck 2009. [Epub ahead of print, doi: 10.1002/hed.21282]
23. Gonzalez IH, Santana P, Gonzalez-Robayna I, et al. Regulation of the expression of prostate apoptosis response protein 4 (Par-4) in rat granulosa cells. Apoptosis 2007;12:769-79
24. Xie J, Guo Q. Par-4 is a novel mediator of renal tubule cell death in models of ischemia-reperfusion injury. Am J Physiol Renal Physiol 2007; 292: F107-15
25. Gurumurthy S, Rangnekar VM. Par-4 inducible apoptosis in prostate cancer cells. J Cell Biochem 2004;91:504-12
26. Boghaert ER, Sells SF, Walid AJ, et al. Immunohistochemical analysis of the proapoptotic protein Par-4 in normal rat tissues. Cell Growth Differ 1997;8:881-90
27. Gurumurthy S, Goswami A, Vasudevan KM, Rangnekar VM. Phosphorylation of Par-4 by protein kinase A is critical for apoptosis. Mol Cell Biol 2005;25:1146-61
28. Garcia-Cao I, Duran A, Collado M, et al. Tumour-suppression activity of the proapoptotic regulator Par4. EMBO Rep 2005;6:577-83
29. Burikhanov R, Zhao Y, Goswami A, et al. The tumor suppressor Par-4 activates an extrinsic pathway for apoptosis. Cell 2009;138:377-88
30. Cho YS, Park YG, Lee YN, et al. Extracellular protein kinase A as a cancer biomarker: its expression by tumor cells and reversal by a myristate-lacking C alpha and RII beta subunit overexpression. Proc Natl Acad Sci USA 2000;97:835-40
31. Chakraborty M, Qiu SG, Vasudevan KM, Rangnekar VM. Par-4 drives trafficking and activation of Fas and FasL to induce prostate cancer cell apoptosis and tumor regression. Cancer Res 2001;61:7255-63
32. El-Guendy N, Rangnekar VM. Apoptosis by Par-4 in cancer and neurodegenerative diseases. Exp Cell Res 2003;283:51-66
33. Goswami A, Burikhanov R, de Thonel A, et al. Binding and phosphorylation of par-4 by akt is essential for cancer cell survival. Mol Cell 2005;20:33-44
34. Kimura M, Furukawa T, Abe T, et al. Identification of two common regions of allelic loss in chromosome arm 12q in human pancreatic cancer. Cancer Res 1998;58:2456-60
35. Youssef EM, Kaneko K, Yatsuoka T, et al. Human BAC contig covering the deleted region in pancreatic cancer at 12q21. DNA Seq 2001;11:541-6
36. Moreno-Bueno G, Fernandez-Marcos PJ, Collado M, et al. Inactivation of the candidate tumor suppressor par-4 in endometrial cancer. Cancer Res 2007;67:1927-34
37. Kranenburg O. The KRAS oncogene: past, present, and future. Biochim Biophys Acta 2005; 1756 (2) : 81-2
38. Riely GJ, Ladanyi M. KRAS mutations: an old oncogene becomes a new predictive biomarker. J Mol Diagn 2008;10:493-5
39. Mao C, Qiu LX, Liao RY, et al. KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of studies. Lung Cancer 2009. [Epub ahead of print, doi:10.1016/j.lungcan. 2009.11.020]
40. Cejas P, Lopez-Gomez M, Aguayo C, et al. KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis. PLoS One 2009; 4 (12) : e8199
41. Dobrzycka B, Terlikowski SJ, Kowalczuk O, et al. Mutations in the KRAS gene in ovarian tumors. Folia Histochem Cytobiol 2009;47:221-4
42. Jang TW, Oak CH, Chang HK, et al. EGFR and KRAS mutations in patients with adenocarcinoma of the lung. Korean J Intern Med 2009;24:48-54
43. Schubbert S, Zenker M, Rowe SL, et al. Germline KRAS mutations cause Noonan syndrome. Nat Genet 2006;38:331-6
44. Neumann TE, Allanson J, Kavamura I, et al. Multiple giant cell lesions in patients with Noonan syndrome and cardio-facio-cutaneous syndrome. Eur J Hum Genet 2009;17:420-5
45. Castagnola P, Giaretti W. Mutant KRAS, chromosomal instability and prognosis in colorectal cancer. Biochim Biophys Acta 2005;1756:115-25
46. Grunicke HH, Maly K. Role of GTPases and GTPase regulatory proteins in oncogenesis. Crit Rev Oncog 1993;4:389-402
47. Vasudevan KM, Ranganathan P, Rangnekar VM. Regulation of Par-4 by oncogenic Ras. Methods Enzymol 2006;407:422-42
48. Pruitt K, Ulku AS, Frantz K, et al. Ras-mediated loss of the pro-apoptotic response protein Par-4 is mediated by DNA hypermethylation through Raf-independent and Raf-dependent signaling cascades in epithelial cells. J Biol Chem 2005;280:23363-70
49. Barradas M, Monjas A, Diaz-Meco MT, et al. The downregulation of the pro-apoptotic protein Par-4 is critical for Ras-induced survival and tumor progression. EMBO J 1999;18:6362-9
50. Ranganathan P, Rangnekar VM. Regulation of cancer cell survival by Par-4. Ann N Y Acad Sci 2005;1059:76-85
51. Moscat J, Diaz-Meco MT. Par-4 keeps the atypical PKCs at bay. Cell Cycle 2003;2:71-2
52. Azmi AS, Ahmad A, Banerjee S, et al. Chemoprevention of pancreatic cancer: characterization of Par-4 and its modulation by 3, 3' diindolylmethane (DIM). Pharm Res 2008;25:2117-24
53. Azmi AS, Wang Z, Burikhanov R, et al. Critical role of prostate apoptosis response-4 in determining the sensitivity of pancreatic cancer cells to small-molecule inhibitor-induced apoptosis. Mol Cancer Ther 2008;7:2884-93
54. Lessene G, Czabotar PE, Colman PM. BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov 2008; 7 (12) : 989-1000
55. Hua C, Zorn S, Jensen JP, et al. Consequences of the t (14;18) chromosomal translocation in follicular lymphoma: deregulated expression of a chimeric and mutated BCL-2 gene. Oncogene Res 1988;2:263-75
56. Cheema SK, Mishra SK, Rangnekar VM, et al. Par-4 transcriptionally regulates Bcl-2 through a WT1-binding site on the bcl-2 promoter. J Biol Chem 2003;278:19995-20005
57. Qiu G, Ahmed M, Sells SF, et al. Mutually exclusive expression patterns of Bcl-2 and Par-4 in human prostate tumors consistent with down-regulation of Bcl-2 by Par-4. Oncogene 1999;18:623-31
58. Boghaert ER, Sells SF, Walid AJ, et al. Immunohistochemical analysis of the proapoptotic protein Par-4 in normal rat tissues. Cell Growth Differ 1997;8:881-90
59. Hamacher R, Schmid RM, Saur D, Schneider G. Apoptotic pathways in pancreatic ductal adenocarcinoma. Mol Cancer 2008;7:64
60. Schneider G, Hamacher R, Eser S, et al. Molecular biology of pancreatic cancer-new aspects and targets. Anticancer Res 2008;28:1541-50
61. Evans JD, Cornford PA, Dodson A, et al. Detailed tissue expression of bcl-2, bax, bak and bcl-x in the normal human pancreas and in chronic pancreatitis, ampullary and pancreatic ductal adenocarcinomas. Pancreatology 2001;1:254-62
62. Azmi AS, Mohammad RM. Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy. J Cell Physiol 2009;218:13-21
63. Boucher MJ, Morisset J, Vachon PH, et al. MEK/ERK signaling pathway regulates the expression of Bcl-2, Bcl-XL, and Mcl-1 and promotes survival of human pancreatic cancer cells. J Cell Biochem 2000;79:355-69
64. Greten FR, Weber CK, Greten TF, et al. Stat3 and NF-kappaB activation prevents apoptosis in pancreatic carcinogenesis. Gastroenterology 2002;123:2052-63
65. Regula KM, Baetz D, Kirshenbaum LA. Nuclear factor-kappaB represses hypoxia-induced mitochondrial defects and cell death of ventricular myocytes. Circulation 2004;110:3795-802
66. Wang Z, Song W, Aboukameel A, et al. TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and invasion in pancreatic cancer. Int J Cancer 2008;123:958-66
67. Gilmore TD. Introduction to NF-kappaB: players, pathways, perspectives. Oncogene 2006;25:6680-4
68. Tian B, Brasier AR. Identification of a nuclear factor kappa B-dependent gene network. Recent Prog Horm Res 2003;58:95-130
69. Baud V, Karin M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 2009;8:33-40
70. Chendil D, Das A, Dey S, et al. Par-4, a pro-apoptotic gene, inhibits radiation-induced NFκB activity and Bcl-2 expression leading to induction of radiosensitivity in human prostate cancer cells PC-3. Cancer Biol Ther 2002;1:152-60
71. El-Guendy N, Zhao Y, Gurumurthy S, et al. Identification of a unique core domain of par-4 sufficient for selective apoptosis induction in cancer cells. Mol Cell Biol 2003;23:5516-25
72. Mollinedo F, Gajate C. Fas/CD95 death receptor and lipid rafts: new targets for apoptosis-directed cancer therapy. Drug Resist Updat 2006;9:51-73
73. Ahmad A, Kong D, Sarkar SH, et al. Inactivation of uPA and its receptor uPAR by 3, 3'-diindolylmethane (DIM) leads to the inhibition of prostate cancer cell growth and migration. J Cell Biochem 2009;107:516-27
74. Ali S, Varghese L, Pereira L, et al. Sensitization of squamous cell carcinoma to cisplatin induced killing by natural agents. Cancer Lett 2009;278:201-9
75. Ali S, Banerjee S, Ahmad A, et al. Apoptosis-inducing effect of erlotinib is potentiated by 3, 3'-diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer. Mol Cancer Ther 2008;7:1708-19
76. Rahman KM, Ali S, Aboukameel A, et al. Inactivation of NF-kappaB by 3, 3'-diindolylmethane contributes to increased apoptosis induced by chemotherapeutic agent in breast cancer cells. Mol Cancer Ther 2007;6:2757-65
77. Li Y, Wang Z, Kong D, et al. Regulation of FOXO3a/beta-catenin/GSK-3beta signaling by 3, 3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in prostate cancer cells. J Biol Chem 2007;282:21542-50
78. Kong D, Li Y, Wang Z, et al. Inhibition of angiogenesis and invasion by 3, 3'-diindolylmethane is mediated by the nuclear factor-kappaB downstream target genes MMP-9 and uPA that regulated bioavailability of vascular endothelial growth factor in prostate cancer. Cancer Res 2007;67:3310-19
79. Bhuiyan MM, Li Y, Banerjee S, et al. Down-regulation of androgen receptor by 3, 3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate cancer cells. Cancer Res 2006;66:10064-72
80. Tokunaga E, Oki E, Egashira A, et al. Deregulation of the Akt pathway in human cancer. Curr Cancer Drug Targets 2008;8:27-36
81. Chonghaile TN, Letai A. Mimicking the BH3 domain to kill cancer cells. Oncogene 2008; 27 (Suppl 1) : S149-57
82. Wang G, Nikolovska-Coleska Z, Yang CY, et al. Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J Med Chem 2006;49:6139-42
83. Zeitlin BD, Joo E, Dong Z, et al. Antiangiogenic effect of TW37, a small-molecule inhibitor of Bcl-2. Cancer Res 2006;66:8698-706
84. Prost P, Ychou M, Azria D. Gemcitabine and pancreatic cancer. Bull Cancer 2002; 89 (Spec No) : S91-5
85. Keleg S, Buchler P, Ludwig R, et al. Invasion and metastasis in pancreatic cancer. Mol Cancer 2003;2:14
86. Macdonald JS, McCoy S, Whitehead RP, et al. A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924) study. Invest New Drugs 2005;23:485-7
87. Van Custem E, van de Velde HKarasek P, et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004;22:1430-8
88. Bramhall SR, Schulz J, Nemunaitis J, et al. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 2002;87:161-7
89. Kindler HL, Friberg G, Singh DA, et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2005;23:8033-40
90. Xiong HQ, Rosenberg A, LoBuglio A, et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter Phase II trial. J Clin Oncol 2004;22:2610-6
91. Stehelin D, Fujita DJ, Padgett T, et al. Detection and enumeration of transformation-defective strains of avian sarcoma virus with molecular hybridization. Virology 1977;76:675-84
92. Summy JM, Gallick GE. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 2003;22:337-58
93. Nalca A, Qiu SG, El-Guendy N, et al. Oncogenic Ras sensitizes cells to apoptosis by Par-4. J Biol Chem 1999;274:29976-83
94. Gallick GE. SRC as a potential therapeutic target in solid tumor oncology. Clin Adv Hematol Oncol 2004;2:435-7